Quirine A. ten Bosch

Dr. Quirine A. ten Bosch

Quantitative Veterinary Epidemiology, Wageningen University, Droevendaalsesteeg 1 (Campus), building no. 107 - E0-182, 6702 PB Wageningen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GEGuido España
Guido España
CHCosmina Hogea
Cosmina Hogea
AGAdrienne Guignard
Adrienne Guignard
QBQuirine A. ten Bosch
Quirine A. ten Bosch
AMAmy C Morrison
Amy C Morrison
TPT. Alex Perkins
T. Alex Perkins
Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine candidates for public health implementation, but efficacy trials are subject to a known bias to estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis of trial data. In light of many well-characterized sources of heterogeneity in dengue virus (DENV) transmission, our goal was to estimate the potential magnitude of this bias in VE estimates for a hypothetical dengue vaccine. To ensure that we realistically modeled heterogeneous exposure, we simulated city-wide DENV transmission and vaccine trial protocols using an agent-based model calibrated with entomological and epidemiological data from long-term field studies in Iquitos, Peru. By simulating a vaccine with a true VE of 0.8 in 1,000 replicate trials each designed to attain 90% power, we found that conventional methods underestimated VE by as much as 21% due to heterogeneous exposure. Accounting for the number of exposures in the vaccine and placebo arms eliminated this bias completely, and the more realistic option of including a frailty term to model exposure as a random effect reduced this bias partially. We also discovered a distinct bias in VE estimates away from the null due to lower detectability of primary DENV infections among seronegative individuals in the vaccinated group. This difference in detectability resulted from our assumption that primary infections in vaccinees who are seronegative at baseline resemble secondary infections, which experience a shorter window of detectable viremia due to a quicker immune response. This resulted in an artefactual finding that VE estimates for the seronegative group were approximately 1% greater than for the seropositive group. Simulation models of vaccine trials that account for these factors can be used to anticipate the extent of bias in field trials and to aid in their interpretation.

3 May 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
QBQuirine A. ten Bosch
Quirine A. ten Bosch
HCHannah Clapham
Hannah Clapham
LLLouis Lambrechts
Louis Lambrechts
VDVeasna Duong
Veasna Duong
PBPhilippe Buchy
Philippe Buchy
TPT. Alex Perkins
T. Alex Perkins
Despite estimates that, each year, as many as 300 million dengue virus (DENV) infections result in either no perceptible symptoms (asymptomatic) or symptoms that are sufficiently mild to go undetected by surveillance systems (inapparent), it has been assumed that these infections contribute little to onward transmission. However, recent blood-feeding experiments with Aedes aegypti mosquitoes showed that people with asymptomatic and pre-symptomatic DENV infections are capable of infecting mosquitoes. To place those findings into context, we used models of within-host viral dynamics and human demographic projections to (1) quantify the net infectiousness of individuals across the spectrum of DENV infection severity and (2) estimate the fraction of transmission attributable to people with different severities of disease. Our results indicate that net infectiousness of people with asymptomatic infections is 80% (median) that of people with apparent or inapparent symptomatic infections (95% credible interval (CI): 0–146%). Due to their numerical prominence in the infectious reservoir, clinically inapparent infections in total could account for 84% (CI: 82–86%) of DENV transmission. Of infections that ultimately result in any level of symptoms, we estimate that 24% (95% CI: 0–79%) of onward transmission results from mosquitoes biting individuals during the pre-symptomatic phase of their infection. Only 1% (95% CI: 0.8–1.1%) of DENV transmission is attributable to people with clinically detected infections after they have developed symptoms. These findings emphasize the need to (1) reorient current practices for outbreak response to adoption of pre-emptive strategies that account for contributions of undetected infections and (2) apply methodologies that account for undetected infections in surveillance programs, when assessing intervention impact, and when modeling mosquito-borne virus transmission. Most dengue virus infections result in either no perceptible symptoms or symptoms that are so mild that they go undetected by surveillance systems. It is unclear how much these infections contribute to the overall transmission and burden of dengue. At an individual level, we show that people with asymptomatic infections are approximately 80% as infectious to mosquitoes as their symptomatic counterparts. At a population level, we show that approximately 88% of infections result from people who display no apparent symptoms at the time of transmission. These results suggest that individuals undetected by surveillance systems may be the primary reservoir of dengue virus transmission and that policy for dengue control and prevention must be revised accordingly.

5 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
GBGebbiena Bron
Gebbiena Bron
KSKathryn Strimbu
Kathryn Strimbu
HCHélène Cecilia
Hélène Cecilia
ALAnita Lerch
Anita Lerch
SMSean M. Moore
Sean M. Moore
QBQuirine A. ten Bosch
Quirine A. ten Bosch
During the past 100 years, Rift Valley fever virus (RVFV), a mosquito-borne virus, has caused potentially lethal disease in livestock, and has been associated with significant economic losses and trade bans. Spillover to humans occurs and can be fatal. Here, we combined data on RVF disease in humans (22 countries) and animals (37 countries) from 1931 to 2020 with seroprevalence studies from 1950 to 2020 (n = 228) from publicly available databases and publications to draw a more complete picture of the past and current RVFV epidemiology. RVFV has spread from its original locus in Kenya throughout Africa and into the Arabian Peninsula. Throughout the study period seroprevalence increased in both humans and animals, suggesting potentially increased RVFV exposure. In 24 countries, animals or humans tested positive for RVFV antibodies even though outbreaks had never been reported there, suggesting RVFV transmission may well go unnoticed. Among ruminants, sheep were the most likely to be exposed during RVF outbreaks, but not during periods of cryptic spread. We discuss critical data gaps and highlight the need for detailed study descriptions, and long-term studies using a one health approach to further convert the patchwork of data to the tale of RFV epidemiology.

20 March 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
TPT. Alex Perkins
T. Alex Perkins
RRRobert C Reiner
Robert C Reiner
GEGuido España
Guido España
QBQuirine A. ten Bosch
Quirine A. ten Bosch
AVAmit Verma
Amit Verma
DSDavid L Smith
David L Smith
Prophylactic vaccination is a powerful tool for reducing the burden of infectious diseases, due to a combination of direct protection of vaccinees and indirect protection of others via herd immunity. Computational models play an important role in devising strategies for vaccination by making projections of its impacts on public health. Such projections are subject to uncertainty about numerous factors, however. For example, many vaccine efficacy trials focus on measuring protection against disease rather than protection against infection, leaving the extent of breakthrough infections (i.e., disease ameliorated but infection unimpeded) among vaccinees unknown. Our goal in this study was to quantify the extent to which uncertainty about breakthrough infections results in uncertainty about vaccination impact, with a focus on vaccines for dengue. To realistically account for the many forms of heterogeneity in dengue virus (DENV) transmission, which could have implications for the dynamics of indirect protection, we used a stochastic, agent-based model for DENV transmission informed by more than a decade of empirical studies in the city of Iquitos, Peru. Following 20 years of routine vaccination of nine-year-old children at 80% coverage, projections of the proportion of disease episodes averted varied by a factor of 1.76 (95% CI: 1.54–2.06) across the range of uncertainty about breakthrough infections. This was equivalent to the range of vaccination impact projected across a range of uncertainty about vaccine efficacy of 0.268 (95% CI: 0.210–0.329). Until uncertainty about breakthrough infections can be addressed empirically, our results demonstrate the importance of accounting for it in models of vaccination impact.

3 January 2013 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
WSWilma A. Stolk
Wilma A. Stolk
QBQuirine A. ten Bosch
Quirine A. ten Bosch
SVSake J De Vlas
Sake J De Vlas
PFPeter U Fischer
Peter U Fischer
GWGary J Weil
Gary J Weil
AGAnn S Goldman
Ann S Goldman
The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many countries. However, progress has been slow in some countries, and others have not yet started their mass drug administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per year would affect program duration and costs by using computer simulation modeling and cost projections. We used the LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust. Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be implemented. This strategy may improve prospects for global elimination of LF by the target year 2020. The Global Program to Eliminate Lymphatic Filariasis (LF) employs annual mass drug administration (MDA) of antifilarial drugs to reduce infection rates in populations and interrupt transmission. While this program is working well in many countries, progress has been slow in others, and some countries have not yet started MDA programs. We used computer simulation modeling and cost projections to study how increasing MDA frequency from once to twice per year would affect program duration and costs. Our results suggest that semiannual MDA is likely to reduce the time required to eliminate LF by 50% and reduce total program costs (excluding the cost of donated drugs) in most situations. For these and other reasons, we expect semiannual MDA to be superior to annual MDA in most endemic settings. Semiannual MDA should be considered as a means of accelerating LF elimination in areas where it can be implemented, because this may improve prospects for global elimination of LF by the target year 2020.

18 March 2008 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ADAmalia Dolga
Amalia Dolga
INIngrid M. Nijholt
Ingrid M. Nijholt
AOAnghelus Ostroveanu
Anghelus Ostroveanu
QBQuirine A. ten Bosch
Quirine A. ten Bosch
PLPaul G.M. Luiten
Paul G.M. Luiten
UEUlrich Eisel
Ulrich Eisel
Statins are widely used as medication to lower cholesterol levels in human patients. In addition, it was recently reported that they also reduce the incidence of stroke and progression of Alzheimer's disease when prophylactically administered. To dat